CORRECTION: Biomarin Pharmaceutical Q2 Adj EPS $0.54 Beats $0.47 Estimate, Sales $595.27M Beat $591.46M Estimate
Portfolio Pulse from Happy Mohamed
Biomarin Pharmaceutical reported Q2 earnings of $0.54 per share, beating the analyst consensus estimate of $0.47 by 14.89%. This is a 260% increase over earnings of $0.15 per share from the same period last year. The company also reported quarterly sales of $595.27 million, beating the analyst consensus estimate of $591.46 million by 0.65%. This is a 11.52% increase over sales of $533.80 million the same period last year.
August 01, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biomarin Pharmaceutical's Q2 earnings and sales beat estimates, showing significant YoY growth. This positive financial performance could boost investor confidence and potentially drive the stock price up in the short term.
Biomarin Pharmaceutical's Q2 earnings and sales exceeded analyst estimates, indicating strong financial performance. This positive news is likely to increase investor confidence in the company, which could lead to increased demand for the stock and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100